 Memorial Sloan Kettering Cancer Centers MSK has notified the FDA of a fatal serious adverse event SAE associated with a patient in Phase 1 study of Atara Biotherapeutics Incs NASDAQ: ATRA autologous mesothelin CAR T, ATA2271. MSK has voluntarily paused enrollment of new patients in the study temporarily while additional information regarding the case is gathered and reviewed. 